The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

A popular diabetes drug just got a major new approval -- and it could be a game-changer for millions of Americans at risk for ...

People who have been using Ozempic have been complaining of a bizarre side-effect, which has been nicknamed 'Ozempic butt'. The phenomenon has swept the US and overseas, as people - including ...

President Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ending birthright citizenship, are quickly slapped down in ...

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Heartseed Inc. and Novo Nordisk - in partnership since June 2021 - have announced that the first patient has been successfully dosed in a clinical study with HS-001, a cell therapy designed to ...